To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below = 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two-year follow-up.
This study evaluates 6142 treatment-naïve eyes, with focus on a subgroup of 780 eyes with final VA outcome of = 35 letters, regarding differences of baseline characteristics, change of VA, number of injections and choice of drug to predict visual outcome.
Patients with final VA = 35 letters were older; p 35 letters presented the following baseline lesion locations; p = 0.001; 61% vs. 57% subfoveal, 18% vs. 21% juxtafoveal and 4% vs. 6% extrafoveal. Lesion size, in the group with final VA = 35 letters, was 2805 ± 2093 µm vs. 2440 ± 1637 µm in the group with a VA of > 35 letters; p = 0.005. A logistic regression analysis including baseline VA, best- or worse-seeing eye, age, membrane size, membrane location, symptom duration showed VA; p =